Newsroom | 94886 results

SHANGHAI--(BUSINESS WIRE)--YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene-editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for YOLT-202, the company’s investigational in vivo base-editing therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). The FDA approval enables the initiation of an open-label, single-dose expansion Phase 2/3 clinical study...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 60,655 shares of its common stock to five newly hired employees, consisting of inducement stock options to purchase an aggregate of 24,506 shares of common stock and inducement restricted stock units, covering an aggregate of 36,149 shares of its common stock. The awards are subject to all terms and conditions and other provisio...

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on March 12, 2026 (Grant Date), the Compensation Committee of the Company’s Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 51,000 shares of Class A common st...

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its fourth quarter and full year financial results and business highlights o...

PHILADELPHIA--(BUSINESS WIRE)--GSK’s RSV vaccine, AREXVY, approved in US for expanded age indication in adults aged 18–49 years at increased risk...

BERKELEY, Calif.--(BUSINESS WIRE)--We are enabling validation and rapid iteration so researchers can turn cofolding models into scientific infrastructure that speeds drug discovery...

PHOENIX--(BUSINESS WIRE)--Western Alliance Bank (NYSE: WAL) today announced the launch of its specialized Healthcare commercial banking team, led by industry executive Jennifer Hwang. Hwang will build and lead a Healthcare banking team that will deliver strategic, integrated financial advice and solutions to clients across subsectors including specialty pharmaceuticals, home health and hospice, medical device, ambulatory surgical centers and providers. Healthcare is the latest addition to Weste...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC (“Ignite”), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite’s functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be cap...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2025 and provided a business update. “Over the last year, we significantly advanced the MOLBREEVI development program,” said Matt Pauls, Chair and Chief Executive Officer, Savara. “With the filing of the BLA, an assigned PDUFA date of August 22nd, and submiss...